HSP90 inhibitors reduce cholesterol storage in Niemann-Pick type C1 mutant fibroblasts

Nina H. Pipalia, Syed Z. Saad, Kanagaraj Subramanian, Abigail Cross, Aisha al-Motawa, Kunal Garg, Brian S. J. Blagg, Len Neckers, Paul Helquist, Olaf Wiest, Daniel Ory, Frederick R. Maxfield

TL;DR

Researchers have found that inhibiting HSP90, a protein chaperone, can effectively reduce cholesterol buildup in cells affected by Niemann-Pick type C1 (NPC1) disease. This approach works by improving the folding and trafficking of the faulty NPC1 protein, offering a promising avenue for developing new treatments for this rare genetic disorder.

What Problem Does This Paper Address?

Niemann-Pick type C1 (NPC1) disease is a severe, inherited disorder characterized by the abnormal accumulation of cholesterol and other lipids within lysosomes and late endosomes (LE/Ly) of cells. This buildup disrupts cellular function and leads to a range of debilitating symptoms, particularly affecting the nervous system. The disease is caused by mutations in the NPC1 gene, which encodes a crucial protein responsible for transporting cholesterol out of these cellular compartments. Over 300 different mutations have been identified, with the I1061T mutation being particularly common. Currently, there are no FDA-approved therapies for NPC1 disease, although some experimental treatments like intrathecal cyclodextrin are being investigated. Previous research by the authors showed that histone deacetylase inhibitors (HDACis) could reduce cholesterol storage in NPC1 mutant cells by enhancing the folding and delivery of the NPC1 protein to LE/Ly. This suggested that manipulating protein chaperones, which assist in protein folding, might be a viable therapeutic strategy. This paper investigates whether targeting HSP90, a major chaperone, could offer a similar or improved therapeutic benefit.

Methods

The study employed several key techniques to investigate the effects of HSP90 inhibitors:

  • Cell Culture: Human NPC1 mutant fibroblasts (specifically GM18453 cells with the I1061T mutation) were used as the primary model system.
  • Filipin Staining and Fluorescence Microscopy: Filipin is a fluorescent stain that binds to unesterified cholesterol. By quantifying the intensity of filipin staining in the perinuclear region (representing LE/Ly), researchers could measure cholesterol accumulation. Automated microscopy systems (ImageXpress Micro) were used for high-throughput imaging and analysis.
  • HSP90 Inhibitor Treatment: A panel of six different HSP90 inhibitors (17-AAG, AUY922, ganetespib, AT13387, SNX2112, and TAS-116) were tested at various concentrations and time points.
  • Western Blotting: This technique was used to measure the expression levels of key proteins, including NPC1, HSP90, HSP70, HSP40, and GAPDH (as a loading control), in response to inhibitor treatment.
  • Endoglycosidase H (EndoH) Assay: This assay was used to assess the proper folding and export of the NPC1 protein from the endoplasmic reticulum (ER). Proteins that have exited the ER become resistant to EndoH digestion.
  • Immunolocalization and Colocalization Studies: Cells were treated with fluorescently labeled LDL (low-density lipoprotein), which is taken up by cells and delivered to LE/Ly. By co-localizing the fluorescently tagged NPC1 protein with LDL, researchers could determine if the mutant NPC1 protein was correctly trafficked to the compartments where cholesterol is released.
  • Overexpression Studies: The researchers transfected cells with plasmids to overexpress HSP70 and HSP40 to investigate their role in rescuing the NPC1 phenotype.
  • Amplex Red Assay: This assay was used to measure total free cholesterol levels in cells as an alternative to filipin staining.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from cell cultures and biochemical assays.

Key Insights and Ideas

  • HSP90 as a Chaperone for NPC1: The study strongly suggests that HSP90 plays a critical role in the proper folding and trafficking of the NPC1 protein. Inhibiting HSP90 appears to "correct" the misfolding and ER retention issues common in NPC1 mutants.
  • Chaperone Network Involvement: The effectiveness of HSP90 inhibitors seems to be linked to their ability to upregulate other chaperones, particularly HSP70 and HSP40. This highlights the complex interplay within the cellular chaperone network.
  • Specificity of HSP90 Inhibition: The study found that inhibiting cytosolic HSP90 (HSP90A) was effective, while inhibiting ER-resident HSP90B (GRP94) was not. This suggests a specific role for cytosolic HSP90 in NPC1 protein maturation.
  • Arimoclomol's Lack of Efficacy: Surprisingly, arimoclomol, a known HSP70 co-inducer, did not show any therapeutic benefit in NPC1 mutant cells, even when combined with an HSP90 inhibitor. This suggests that simply increasing HSP70 levels might not be sufficient, or that arimoclomol has off-target effects at the concentrations tested.

Key Results

  • Cholesterol Reduction: Six different HSP90 inhibitors significantly reduced cholesterol accumulation in NPC1<sup>I1061T</sup> fibroblasts in a dose-dependent manner. AUY922 was found to be the most potent inhibitor.
  • Improved NPC1 Trafficking: HSP90 inhibition led to enhanced delivery of the mutant NPC1 protein from the ER to LE/Ly compartments. This was evidenced by increased EndoH resistance (indicating ER exit) and improved colocalization of NPC1 with internalized LDL in LE/Ly.
  • HSP70 and HSP40 Upregulation: Treatment with HSP90 inhibitors significantly increased the expression of HSP70 and HSP40 proteins.
  • Overexpression Rescues Phenotype: Overexpression of either HSP70 or HSP40 alone was sufficient to reduce cholesterol storage in NPC1<sup>I1061T</sup> fibroblasts, reinforcing their role in NPC1 protein function.
  • No Effect in NPC1 Null Cells: HSP90 inhibitors did not correct cholesterol accumulation in NPC1-null cells, indicating that the observed effect is specific to the presence of a mutant NPC1 protein and not a general bypass mechanism.
  • Arimoclomol Ineffectiveness: Arimoclomol did not reduce cholesterol storage and did not increase HSP70 expression in the tested NPC1 mutant cells.

Limitations and Future Work

  • In Vitro Study: The current study was conducted in cell culture. While promising, these findings need to be validated in animal models and eventually in human clinical trials.
  • Mechanism of HSP70/HSP40 Action: While overexpression of HSP70 and HSP40 rescued the phenotype, the precise molecular mechanisms by which these chaperones interact with the large transmembrane NPC1 protein to improve its folding and function remain to be fully elucidated. The paper suggests potential roles in extending NPC1 lifetime or facilitating ER exit.
  • Arimoclomol's Discrepancy: The lack of efficacy of arimoclomol, despite its reported role in HSP70 induction, warrants further investigation. The authors speculate that the required "mild independent activation of stress" might not have been present in their cell culture model, or that arimoclomol may have off-target effects at higher concentrations.
  • Specificity of HSP90 Inhibition: The study highlights the importance of cytosolic HSP90A. Future work could focus on developing more specific inhibitors targeting this isoform.
  • Combination Therapies: The authors suggest that further exploration of targeting chaperone networks, potentially in combination with other therapeutic strategies, is warranted. The promising effect of HSP90 inhibition and HSP70 overexpression provides a strong basis for developing optimal strategies for NPC1 treatment.

Summary updated

Abstract

Niemann-Pick type C1 (NPC1) disease is a lysosomal lipid storage disorder caused by mutations of the NPC1 gene. More than 300 disease-associated mutations are reported in patients, resulting in abnormal accumulation of unesterified cholesterol, glycosphingolipids, and other lipids in late endosomes and lysosomes (LE/Ly) of many cell types. Previously, we showed that treatment of many different NPC1 mutant fibroblasts with histone deacetylase inhibitors resulted in reduction of cholesterol storage, and we found that this was associated with enhanced exit of the NPC1 protein from the endoplasmic reticulum and delivery to LE/Ly. This suggested that histone deacetylase inhibitors may work through changes in protein chaperones to enhance the folding of NPC1 mutants, allowing them to be delivered to LE/Ly. In this study, we evaluated the effect of several HSP90 inhibitors on NPC1<sup>I1061T</sup> skin fibroblasts. We found that HSP90 inhibition resulted in clearance of cholesterol from LE/Ly, and this was associated with enhanced delivery of the mutant NPC1<sup>I1061T</sup> protein to LE/Ly. We also observed that inhibition of HSP90 increased the expression of HSP70, and overexpression of HSP70 also reduced cholesterol storage in NPC1<sup>I1061T</sup> fibroblasts. However, we did not see correction of cholesterol storage by arimoclomol, a drug that is reported to increase HSP70 expression, at doses up to 0.5 mM. The increase in other chaperones as a consequence of HSP90 improves folding of NPC1 protein and relieves cholesterol accumulation in NPC1 mutant fibroblasts.
BibTeX
@article{pipalia2021hsp,
  author = {Nina H. Pipalia and Syed Z. Saad and Kanagaraj Subramanian and Abigail Cross and Aisha al-Motawa and Kunal Garg and Brian S. J. Blagg and Len Neckers and Paul Helquist and Olaf Wiest and Daniel Ory and Frederick R. Maxfield},
  title = {{HSP90 inhibitors reduce cholesterol storage in Niemann-Pick type C1 mutant fibroblasts}},
  journal = {Journal of Lipid Research},
  year = {2021},
  doi = {10.1016/j.jlr.2021.100114},
}
Figure